Latest News
Learn about what we have been working on, find out what we are interested in, and see our accomplishments!
LEXINGTON, Ky. (Aug. 10, 2023) – Using antibodies derived from alpacas, a University of Kentucky research team has developed a tool that could lead to new therapies to stop the growth of several types of cancer. While cancer researchers have known that a protein called PRL-3 is linked to the growth of colon, breast, lung, skin…
This summer I worked under Evelyn as a research assistant where we investigated different, non-traditional drugs as radiosensitizers for DIPG tumors. I did this through culturing SCC127 cells and injecting them into zebrafish embryos and testing these drugs both with and without radiation to see if the drugs would allow of the resensitization of…
This week I just wrapped up presenting my summer project with Majd on the potential mechanism involving mitochondrial alterations in Amiloride’s targeting of leukemia-initiating cells (LICs) of T-cell lymphoblastic leukemia (T-ALL) through NHE1 inhibition. I was able to look at the mitochondrial phenotype induced by Amiloride treatment and the mitochondrial stress genes involved, all…
Phosphatase of Regenerating Liver-3 (PRL-3) is associated with the progression and spread of cancer, but the limited number of research tools available to study this protein have prevented us from fully understanding of PRL-3’s role in cancer. To address this, we developed nanobodies, or single-domain antibodies derived from alpacas, that specifically target PRL-3. Our…
The increasing number of anti-cancer drugs poses a challenge for doctors who need to choose the best treatment for patients. Precision cancer medicine aims to match a drug with a tumors unique characteristics to maximize its effectiveness. However, current approaches don’t fully consider tumor heterogeneity or differences within the cells that make up the tumor,…
Acute Lymphoblastic Leukemia (ALL) is a common type of cancer primarily affecting children. Unfortunately, patients who experience a relapse of ALL tend to have a poor prognosis. Detecting any remaining cancer cells, called minimal residual disease (MRD), and identifying its spread to the central nervous system (CNS), are crucial factors for predicting the disease’s outcome.…